Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection - a pilot study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F18%3A00077422" target="_blank" >RIV/00023001:_____/18:00077422 - isvavai.cz</a>
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/tan.13387" target="_blank" >https://onlinelibrary.wiley.com/doi/abs/10.1111/tan.13387</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/tan.13387" target="_blank" >10.1111/tan.13387</a>
Alternative languages
Result language
angličtina
Original language name
Efficacy and safety of BORTEZOMIB treatment for refractory acute antibody-mediated rejection - a pilot study
Original language description
A novel therapeutic approach to refractory acute antibody-mediated rejection (AMR) in kidney transplant recipients was applied in 23 patients based on administration of Bortezomib, intravenous corticosteroids, plasmapheresis and Rituximab. Application of Bortezomib regimen led to diminishing of donor-specific antibodies (DSA) to HLA-B (P = 0.004) and HLA-DR (P = 0.0005), but not to HLA-A (P = 0.106) and HLA-DQ antigens (P = 0.18). Patients with good clinical response to treatment had significantly better allograft survival than recipients with continuing deterioration of graft function (P = 0.019). Graft survival after therapy of refractory AMR was significantly worse than survival after first transplantation and was comparable with outcomes after retransplantation. In conclusion, therapy with Bortezomib was well tolerated and effective in decreasing the levels of HLA-B and -DR antibodies, however, was not successful in depleting HLA-A and -DQ DSA.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
HLA
ISSN
2059-2302
e-ISSN
—
Volume of the periodical
92
Issue of the periodical within the volume
Suppl. 2
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
47-50
UT code for WoS article
000454095400005
EID of the result in the Scopus database
2-s2.0-85058900916